Member Info for EmeraldCarrots

Would be good. If they can confirm one or both applications are in the sp would recover quite some........ 3p ish I would have thought.

Tbow112

"Angle's Parsortix is the only viable machine for catching cancer circulating tumor cells (CTC's) for DNA analysis. "

This is, of course, not correct."

==========================

Or is it? I define "viable" as in catching CTC's that are "label free". As in pure and not contaminated with antibodies or caught with loads of white blood cells at the same time. Also it catches roughly the same amount as the best seller cellsearch and is a faster and cheaper process. But with cellsearch the CTC's are caught using antibodies. So I think Parsortix is the most viable to use if you want to do DNA analysis on the CTC's.

All IMHO.

1. CE certification for the Genedrive® CYP2C19.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1.

All due by end of May, which is of course is THIS WEEK.

Friday? Oh err....TOMORROW?

Just half a dozen orders and take off. Come on Angle's sales. Get your act together!!!

"Revenues for the year up 31% to £2.9 million (FY23: £2.2 million)".

"In May 2024, ANGLE announced a second contract with AstraZeneca. Under the terms of the agreement, initially valued at £550,000, with an additional £120,000 added through an expanded scope,".

=================================

So £670,000 of that was ONE of the Astrazeneca contracts, or about 23%.

The other Astra one was £150,000 and the Eisai one £250,000.

We know they have been advertising for more lab people.

So I guess with Parsortix machine sales and consumables revenue Angle would need just 2 orders of similar size to Astras bigger order to easily increase revenue. So beating the year ended 31 December 2024 revenue suddenly seems far more likely.

This is good.

All IMHO.

With large Pharma so far on their Services side all landed last year and finished ealier this year.

2 with Astrazeneca ($200 Billion market cap) and one with Eisai Inc. of Japan ($15 billion market cap.).

All 3 were completed ok.

I would ask why no other ones have materialised since?

What are their sales side doing?????????????

Being able to boast you have contracts with Astra has got to have a lot of weight.

Same with Eisai, but not as much, although they are a Japanese top 100 Co.

It is very odd. Of course they might announce another few contracts with Astra or Eisal tomorrow but even so...........

Not impressed with their sales side to be honest.

All IMHO.

At these totally insane sp levels before making a bid. Angle's Parsortix is the only viable machine for catching cancer circulating tumor cells (CTC's) for DNA analysis. That is in the whole World. I honestly can't believe the sp. It's like having a brand new Rolls Royce with a price tag of £500 quid on your driveway.

All IMHO.

End of.

RaiseworldC.

This situation is totally insane IMHO.

Deliver live, intact circulating tumour cells (CTC's) that are perfect for analysis, including DNA. Also, Angle's combined CtDna and CTC analysis has been proven to find about twice as many biomarkers as CtDna analysis alone. CtDna analysis is an existing multi-billion $ industry one of its main aims being to find biomarkers so a cancer can be targeted by modern drugs. The sp is preposterous.

=============================

Other systems currently available to catch the CTC's either contaminate them during the catching process, the CTCs are swamped with white blood cells, or not enough of them are caught. I mean this is the key here. Illumina, or any other Company simply cannot do this without live, intact CTC's that are not contaminated. This is the crazy situation at the moment I believe.

Illumina could corner the market by buying Angle Plc.

Watch this space!

All IMHO.

Analysis without Angle's Parsortix machine, can they? They just can't as far as I am aware. Other systems currently available to catch the CTC's either contaminate them during the catching process, the CTC's are swamped with white blood cells, or not enough of them are caught. I mean this is the key here. Illumina, or any other Company simply cannot do this without live, intact CTC's that are not contaminated.

This is the crazy situation at the moment I believe.

Illumina could corner the market by buying Angle Plc.

Watch this space!

All IMHO.

- And Angle's sales side cannot even get enough orders to break even. You could not make it up. It is crazy.

Analysis without Angle's Parsortix machine, can they? They just can't as far as I am aware. Other systems currently available to catch the CTC's either contaminate them during the catching process, the CTC's are swamped with white blood cells, or not enough of them are caught. I mean this is the key here. Illumina, or any other Company simply cannot do this without live, intact CTC's that are not contaminated.

This is the crazy situation at the moment I believe.

Illumina could corner the market by buying Angle Plc.

Watch this space!

All IMHO.

Disagree. Angle have probably the best circulating tumour cell capture machine in the entire World and so far, they have not even managed to break even. Anyone with a brain can see there is something very wrong on the sales side. If they can sort this out, and I see no reason why not, in a few years from now they will be making tens if not hundreds of millions.

All IMHO.

Include Mr Newland. After all he is the one that has said in numerous presentations he is talking to many Companies. Maybe they were discussing the weather? LOL! I believe Parsortix is the best machine for catching circulating tumour cells (CTC's) to analyse and do DNA tests on. In fact, how will any Company do that without it? The best seller CellSearch is great at counting the number of CTCs, but no good for analysing them/doing DNA tests as it uses antibodies and so the samples are contaminated. Not only that Parsortix is cheaper and faster! Which begs the question why does Angle struggle to sell the machine, and the services it offers. It does not compute. There must be something very wrong with the way the talks are handled. If it is cost then surely Angle could drop the price to get things moving. All roads lead back to Mr Newland. He needs to let someone else do the negotiating and keep well out of it I think.

All IMHO.

But was it a buy or a sell.

Most likely a sell 1st thing this morning I think but we will never know.

1. CE certification for the Genedrive® CYP2C19.

2. A further five Group 2 hospitals phased to go-live from May 2025 for the Genedrive® MT-RNR1.

All due by end of May, which is of course is THIS WEEK.

Thursday? Oh err....TOMORROW?

Mark my words. Unless the Chairman stops Newland from getting involved with sales we are all in trouble. Newlands track record for sales is appauling. He is no good at it. Angle have probably the best CTC analysis system anywhere in the entire World, yet they striggle to do deals. Newland is the problem IMHO. Either remove him from the sales side or remove him from Angle Plc. That is my opinion.

All IMHO.

I think the Chairman needs to tell Newland to not get involved AT ALL in sales negotiations. If he does he should be sacked. I suspect Newland is the problem at Angle Plc. In fact if he goes the sp might take off.

All IMHO.

Involved with all these discussions, nearly all of which lead to nothing. He needs to leave sales to somone who has a GOOD, or even FAIR, record. His track record as far as I can see is terrible. If he wrote down how many potential clients he has negotiated with and failed to do a deal with I suspect it would be almost unbelievable. He needs to leave sales to someone else.

All IMHO.

Angle have. It points to weak management and for that Newland and Griffiths are now in the firing line. Parsortix is probably the best system for capturing circulating tumour cells (CTC's) IN THE ENTIRE WORLD. Please check it out. I have extensively. The biggest selling system is Cellsearch, but it has one huge drawback. Cellsearch was created primarily to count the amount of CTC's in a blood sample and it does that well. However, to catch the CTC's that system uses antibodies and those contaminate the sample. That means the samples are less than ideal for analysis and similar for DNA analysis. This is key. Parsortix delivers pure, live, and intact samples ideal for analysis and perfect for DNA analysis. Quite how the management at Angle have not done better is astounding.

All IMHO.